要让医疗器械创新发展真正驶入快车道，各级药品监管部门须以"春雨行动"为契机，正确把握安全监 管、产业发展与为民服务的关系，做到"保安全"与"促发展"有机统一。 （来源：中国医药报） 转自：中国医药报 □ 本报特约评论员 创新是引领发展的第一动力，是医疗器械产业高质量发展的生命力。2025年4月，国家药监局启动"春雨 行动"，聚焦打通临床创意到产品上市的全链条堵点，推动医疗器械源头创新高效转化。短短数月内， 11个试点地区积极探索，涌现出一批新做法和新成效，推动我国医疗器械创新生态体系建设迈入新阶 段，也彰显了药品监管部门统筹发展与安全、服务新质生产力的战略远见。 好雨知时节，当春乃发生。正如春雨催生春意，催发生机和活力。"春雨行动"并非简单征集临床研究成 果项目，而是构建覆盖"需求挖掘—平台对接—审评提速—政策协同"的全链条服务体系，着力破解长期 存在的"临床需求找不到企业承接、企业研发找不到临床痛点"难题。其核心是以临床价值为导向，"从 患者中来、到患者中去"，真正践行"监管为民"理念，为医疗器械创新发展提供不竭动力。 各地因地制宜的探索，印证了"春雨行动"的可操作性：广东省药监局以"四个一"落实"春雨行动 ...

Core Viewpoint - The core discussion revolves around the application boundaries of "AI + healthcare," emphasizing the need for AI to be an "assistant" rather than a replacement for healthcare professionals, while also addressing regulatory gaps and establishing a dynamic cross-departmental regulatory mechanism [1][2][3]. Group 1: Application Boundaries and Concerns - The refusal to integrate AI into hospital electronic medical record systems highlights concerns about young doctors becoming overly reliant on AI, potentially hindering their clinical thinking development [1]. - Experts argue that AI should enhance patient care without compromising the growth of medical professionals, suggesting a shift in perspective where AI serves to remind and verify clinical thinking rather than replace it [1][2]. - The debate centers on three main issues: prioritizing the cultivation of doctors' skills versus ensuring patient benefits, defining AI's role as a tool versus a potential decision-maker, and managing risks through either preemptive regulation or post-implementation adjustments [2]. Group 2: AI's Role in Healthcare - AI is increasingly being integrated into various clinical scenarios, from diagnostic imaging to intelligent pre-consultation and monitoring, with a significant rise in compliance and clinical penetration [3]. - By December 2025, 207 AI medical devices are expected to receive Class III medical device registration, indicating a maturation of AI in fields like biopharmaceuticals and diagnostic assistance [3]. - The essence of "AI + healthcare" is to optimize medical service processes and address resource shortages, reinforcing that AI is a supplement rather than a substitute for healthcare professionals [3][4]. Group 3: Risk and Ethical Challenges - The global market for AI healthcare solutions is projected to grow from $13.7 billion in 2022 to $155.3 billion by 2030, with China's market expected to reach $16.83 billion, indicating explosive growth opportunities [6]. - However, challenges such as commercialization, ethical dilemmas, and regulatory risks persist, particularly concerning data privacy, algorithm biases, and the opaque nature of AI decision-making [7][8]. - Ethical issues include patient awareness of AI involvement in their care, algorithm fairness, and the potential widening of the healthcare resource gap due to high costs of AI products [8]. Group 4: Regulatory Framework and Recommendations - Current regulations identify healthcare institutions and professionals as responsible parties, with AI positioned as an auxiliary tool, but lack detailed, dynamic control mechanisms for AI's unique challenges [10]. - Recommendations include establishing a risk classification system for AI medical products, creating an algorithm registration and review mechanism, and developing a risk warning platform to monitor AI applications in real-time [11]. - A regulatory sandbox mechanism is suggested for innovative AI healthcare products, allowing controlled exploration while adapting regulations to keep pace with technological advancements [11].

Core Viewpoint - The article highlights the recent policy support from the Shanghai government aimed at promoting high-quality development in the pharmaceutical and medical device industries, focusing on innovation and regulatory reforms [1][4][6]. Group 1: Policy Support and Regulatory Reforms - The Shanghai government has issued measures to support clinical research for innovative traditional Chinese medicine (TCM) and the development of classic TCM formulas [1][5]. - Clinical trial review and approval timelines for eligible innovative drugs will be shortened to 30 working days, with efforts to promote pilot experiences [4][7]. - The establishment of a service list for key research products in areas such as cell and gene therapy, rare diseases, and artificial intelligence medical devices is emphasized [4][5]. Group 2: Focus on Innovation in Medical Devices and Pharmaceuticals - The article discusses the encouragement of medical institutions to accelerate the development and use of self-researched in vitro diagnostic reagents [7]. - It mentions the establishment of a standardized mechanism for collecting real-world evidence from human experience data to support drug registration applications [5][6]. - The article outlines the importance of enhancing clinical data standardization and the establishment of an evaluation mechanism for innovative medical devices based on clinical value [4][5]. Group 3: Market Outlook and Investment Opportunities - Several brokerage firms express optimism about the innovation in the medical device and pharmaceutical sectors, particularly in the context of recent market adjustments [2][8]. - The article notes that the pharmaceutical sector's fundamentals remain strong, with a focus on innovative drugs and the potential for recovery in underperforming segments [9][10]. - It highlights the expected growth in the small nucleic acid drug sector, driven by technological breakthroughs and increased commercialization [9][10].

Core Viewpoint - The Shanghai Municipal Government has issued measures to deepen the reform of drug and medical device regulation, aiming to promote high-quality development in the pharmaceutical industry, focusing on key areas such as cell and gene therapy, rare diseases, and pediatric medications [1] Group 1: Key Areas of Focus - The measures emphasize the importance of specific fields and products, including cell and gene therapy, rare diseases, pediatric medications, high-quality first generic drugs, artificial intelligence medical devices, medical robots, brain-machine interfaces, particle therapy equipment, and innovative traditional Chinese medicine diagnostic and treatment devices [1] Group 2: Regulatory Support - A service list for key varieties under research will be established, providing proactive guidance in clinical trials, registration and listing, inspections, and production licensing [1]

Core Viewpoint - The Shanghai Municipal Government has issued measures to enhance the regulation of pharmaceuticals and medical devices, aiming to promote high-quality development in the pharmaceutical industry [1] Group 1: Regulatory Enhancements - Strengthening standard leadership by actively participating in the formulation and revision of national standards for pharmaceuticals and medical devices, as well as coordinating international standards [1] - Promoting the standardization research of cutting-edge technologies such as artificial intelligence medical devices, medical robots, brain-computer interfaces, particle therapy equipment, innovative traditional Chinese medicine diagnostic devices, and cell and gene therapy [1] Group 2: Traditional Chinese Medicine Standards - Continuing the research on standards for traditional Chinese medicine pieces, formula granules, and medical devices, relying on international standardization platforms like the International Organization for Standardization/Traditional Chinese Medicine Technical Committee (ISO/TC249) to establish international standards for traditional Chinese medicine [1] Group 3: Digitalization and Traceability - Supporting the formulation of group standards for the digital traceability of the production processes of pharmaceuticals and medical devices [1]

Core Viewpoint - Zhejiang Province has launched 20 specific reform measures to enhance the quality of the pharmaceutical and medical device industry, aiming for high-quality development through comprehensive regulatory reforms [1][5]. Group 1: Reform Measures - The implementation plan focuses on five key areas to enhance innovation capabilities, including strengthening the "three medical" collaborative mechanism and improving intellectual property protection [1]. - Zhejiang will optimize the review and approval process for drug changes and implement a "research-review linkage" for medical devices, reducing the review time for major changes to within 60 working days [2]. - A key product list will be compiled to provide comprehensive communication and guidance services for products in critical areas such as cancer and cardiovascular diseases, as well as for urgently needed and rare disease medications [3]. Group 2: Regulatory Capacity Building - The province will advance the research and application of new regulatory tools, standards, and methods, including evaluating the maturity of artificial intelligence medical device algorithms [3]. - The plan aims to enhance the overall safety level and innovation capabilities of drug regulation in Zhejiang, targeting international advanced standards by 2035 [1]. Group 3: Broader Implications - The reforms are expected to significantly promote the high-quality development of Zhejiang's pharmaceutical industry and provide a model for national regulatory reforms in the pharmaceutical and medical device sectors [5].

Core Insights - The approval of innovative medical devices in China has reached a historical high, with 323 devices approved to date, reflecting a significant acceleration in regulatory innovation and support for high-end medical device development [1][2][5] Regulatory Developments - The National Medical Products Administration (NMPA) has implemented special reviews for innovative medical devices that are domestically created, internationally leading, and clinically valuable, aiming to optimize the review process [1][2] - The NMPA plans to enhance the legal and standard framework, increase support for research and development, and improve the efficiency of reviews and approvals [1][2] Industry Trends - The number of approved innovative medical devices has been increasing annually, with a 87.5% year-on-year growth in the first half of 2025 [2] - The domestic medical imaging industry has seen improvements in the supply chain and production capabilities, with many mid-to-low-end products achieving domestic substitution [2][3] Challenges in Domestic Production - Despite advancements, there are still significant challenges in foundational research, software development, and reliance on imported key components [3][4] - The overall market share of domestic high-end medical imaging equipment remains low, indicating ongoing dependency on foreign technology [3][4] Strategic Initiatives - The NMPA has established innovation cooperation platforms for artificial intelligence and biomaterials to facilitate the transformation of research into practical applications [5] - The Ministry of Industry and Information Technology and the NMPA have announced initiatives to focus on key materials and technologies to enhance domestic production capabilities [5] Expert Consultation Mechanism - The NMPA has introduced an expert consultation mechanism to guide innovative medical device companies through the development and approval process, ensuring comprehensive understanding of cutting-edge technologies [7][8] - The expert consultation process includes a diverse pool of approximately 2,500 experts across various medical and technical fields to support the review and evaluation of innovative products [8][9] Focus Areas for Future Development - Future research in artificial intelligence medical devices is expected to concentrate on wireless diagnostics, digital therapies, brain-machine interfaces, and flexible wearable devices [6]

Core Insights - The forum on "Medical Device Technology Review and High-Quality Development" highlighted the rapid growth and innovation in Beijing's medical device industry, with a projected revenue exceeding 1 trillion yuan in 2024 [1][3] - Beijing has established itself as a national innovation hub for the pharmaceutical industry, with over 81 approved Class III innovative medical devices, accounting for more than 20% of the national total [1][3] - The city is leading in the number of artificial intelligence medical products and surgical robots, further solidifying its position in the medical device sector [1][3] Industry Development - The medical device industry is increasingly recognized for its importance in the health sector, with Beijing forming significant advantages through policy support and industry collaboration [3] - As of 2024, the medical device industrial output value is expected to reach 48 billion yuan, with retail and wholesale values at 390 billion yuan [3] - The Beijing Drug Administration has implemented measures to streamline the review and approval process, reducing the average review time for Class II medical devices to 43 working days [3] Innovation and Regulation - The Beijing Economic and Technological Development Area (Yizhuang) is a key area for the development of the medical and health industry, housing over 5,000 enterprises and accounting for nearly half of the city's output [4] - Yizhuang has entered 56 products into the national special review process for innovative medical devices, with 25 approved for market launch [4] - The area aims to create a world-class medical device industry cluster through a dual-driven approach of foreign investment and local ecosystem development [5] Expert Support and Collaboration - The National Medical Products Administration's Medical Device Technical Review Center has over 2,500 experts, including 41 academicians, providing technical support for the review process [6] - A collaborative platform for innovative biomaterials was established to address critical issues in the field, emphasizing the strategic importance of mastering core technologies [7] Clinical Applications - The forum discussed the regulatory focus on specific medical devices, such as orthokeratology lenses, with domestic products accounting for two-thirds of the market [8] - Artificial intelligence medical devices are generating numerous clinical application scenarios, enhancing medical supply capabilities and optimizing treatment processes [9]

Core Insights - The "Results Transformation Forum" focuses on the integration of high-performance medical device technology and innovation, addressing the needs for deep collaboration between industry, academia, and research [1][3] Group 1: Forum Overview - The forum is themed "New Quality Building Dreams, Medical-Engineering Integration" and is organized by the Guangdong Provincial Association for Science and Technology, with eight sub-forums dedicated to academic sharing, paper competitions, industry exhibitions, and collaboration agreements [3] - The forum aims to promote technological and industrial innovation in the high-performance medical device sector, which is crucial for improving disease diagnosis and enhancing public health [3] Group 2: Industry Trends - The global population aged 60 and above is projected to reach one-sixth by 2030 and 2.1 billion by 2050, leading to a more diverse and economically viable demand for medical device services [3] - China's medical device industry has established a comprehensive development ecosystem, with increasing domestic enterprise numbers and enhanced product export capabilities [3] Group 3: Technological Advancements - The development of artificial intelligence (AI) in medical devices is accelerating, with AI technologies accounting for approximately one-third of the approved Class III medical devices in 2024, particularly in medical imaging [4] - Experts emphasize the need for deeper medical-engineering integration to overcome existing bottlenecks in diagnosis and treatment pathways, leveraging AI's rapid advancements for high-end medical device innovation [4]

Core Viewpoint - The article outlines Suzhou's strategic plan to accelerate the development of the "Artificial Intelligence+" city initiative, aiming to establish a robust AI ecosystem by 2026, including significant investments and talent development [1][2][3]. Group 1: Investment and Funding - Suzhou plans to establish an AI fund cluster exceeding 50 billion yuan by 2026 [1]. - The city aims to achieve 50 key core technology breakthroughs and accumulate over 13,000 high-value patents in the AI sector by the end of 2026 [1]. Group 2: Talent Development - By 2026, Suzhou aims to cultivate 240 leading talents in the AI field and establish 15 various talent training platforms and bases [2]. - The city will enhance its talent introduction, training, evaluation, and incentive mechanisms, focusing on attracting high-level and innovative young talents [2]. Group 3: Enterprise and Industry Growth - Suzhou targets the cultivation of 50 intelligent native enterprises, 15 unicorn companies, and 100 city-level unicorn nurturing enterprises by 2026 [2]. - The city plans to nurture 490 provincial-level specialized and innovative enterprises and 1,200 high-tech enterprises in the AI sector by the end of 2026 [3]. Group 4: Infrastructure and Ecosystem Development - Suzhou will select 20 city-level AI industrial parks and develop 3 benchmark parks and 5 characteristic parks to enhance industrial agglomeration effects [3]. - The city is focused on developing embodied intelligence industries and building a complete industrial chain for intelligent vehicle networking [3].